Table II.
Demographics and Selected Clinical Characteristics at Baseline
| Lisinopril Monotherapy (n=130) | Carvedilol CR Monotherapy (n=131) | Carvedilol CR + Lisinopril Combination Therapy (n=393) | Total (N=654) | |
|---|---|---|---|---|
| Age, mean ± SD, y | 52.2±10.6 | 53.9±9.6 | 53.2±9.7 | 53.1±9.9 |
| Age, No. (%) | ||||
| <65 y | 118 (91) | 111 (85) | 347 (88) | 576 (88) |
| ≥65 y | 12 (9) | 20 (15) | 46 (12) | 78 (12) |
| Sex, No. (%) | ||||
| Female | 49 (38) | 51 (39) | 132 (34) | 232 (35) |
| Male | 81 (62) | 80 (61) | 261 (66) | 422 (65) |
| Race, No. (%) | ||||
| White | 85 (65) | 88 (68) | 244 (62) | 417 (64) |
| African American | 40 (31) | 33 (25) | 121 (31) | 194 (30) |
| Other | 5 (4) | 8 (6) | 23 (6) | 36 (6) |
| Diabetes status at baseline, No. (%) | ||||
| No | 96 (74) | 105 (80) | 296 (75) | 497 (76) |
| Yes | 34 (26) | 26 (20) | 97 (25) | 157 (24) |
| Disease history, No. (%) | 130 | 131 | 393 | 654 |
| Treatment‐naïve | 37 (28) | 40 (31) | 106 (27) | 183 (28) |
| Controlled with 1 drug | 36 (28) | 47 (36) | 149 (38) | 232 (35) |
| Controlled with 2 drugs | 55 (42) | 42 (32) | 129 (33) | 226 (35) |
| Controlled with ≥3 drugs | 2 (2%) | 2 (2) | 9 (2) | 13 (2) |
| Baseline sitting SBP, mean ± SD, mm Hg | 149.0±11.6 | 149.9±12.5 | 147.2±12.4 | 148.1±12.3 |
| Baseline sitting DBP, mean ± SD, mm Hg | 95.3±7.8 | 96.2±6.9 | 95.5±7.1 | 95.6±7.2 |
| Stage of hypertension, No. (%) | 130 | 131 | 393 | 654 |
| Stage I | 64 (49) | 61 (47) | 195 (50) | 320 (49) |
| Stage II | 55 (42) | 59 (45) | 161 (41) | 275 (42) |
| Other | 11 (8) | 11 (8) | 37 (9) | 59 (9) |
Abbreviations: DBP, diastolic blood pressure; SBP, systolic blood pressure.